Cargando…

Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome

Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications t...

Descripción completa

Detalles Bibliográficos
Autores principales: Milacic, Marija, Haw, Robin, Rothfels, Karen, Wu, Guanming, Croft, David, Hermjakob, Henning, D’Eustachio, Peter, Stein, Lincoln
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712731/
https://www.ncbi.nlm.nih.gov/pubmed/24213504
http://dx.doi.org/10.3390/cancers4041180
_version_ 1782277109145665536
author Milacic, Marija
Haw, Robin
Rothfels, Karen
Wu, Guanming
Croft, David
Hermjakob, Henning
D’Eustachio, Peter
Stein, Lincoln
author_facet Milacic, Marija
Haw, Robin
Rothfels, Karen
Wu, Guanming
Croft, David
Hermjakob, Henning
D’Eustachio, Peter
Stein, Lincoln
author_sort Milacic, Marija
collection PubMed
description Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics.
format Online
Article
Text
id pubmed-3712731
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37127312013-08-05 Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome Milacic, Marija Haw, Robin Rothfels, Karen Wu, Guanming Croft, David Hermjakob, Henning D’Eustachio, Peter Stein, Lincoln Cancers (Basel) Article Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics. MDPI 2012-11-08 /pmc/articles/PMC3712731/ /pubmed/24213504 http://dx.doi.org/10.3390/cancers4041180 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Milacic, Marija
Haw, Robin
Rothfels, Karen
Wu, Guanming
Croft, David
Hermjakob, Henning
D’Eustachio, Peter
Stein, Lincoln
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title_full Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title_fullStr Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title_full_unstemmed Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title_short Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
title_sort annotating cancer variants and anti-cancer therapeutics in reactome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712731/
https://www.ncbi.nlm.nih.gov/pubmed/24213504
http://dx.doi.org/10.3390/cancers4041180
work_keys_str_mv AT milacicmarija annotatingcancervariantsandanticancertherapeuticsinreactome
AT hawrobin annotatingcancervariantsandanticancertherapeuticsinreactome
AT rothfelskaren annotatingcancervariantsandanticancertherapeuticsinreactome
AT wuguanming annotatingcancervariantsandanticancertherapeuticsinreactome
AT croftdavid annotatingcancervariantsandanticancertherapeuticsinreactome
AT hermjakobhenning annotatingcancervariantsandanticancertherapeuticsinreactome
AT deustachiopeter annotatingcancervariantsandanticancertherapeuticsinreactome
AT steinlincoln annotatingcancervariantsandanticancertherapeuticsinreactome